Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the third quarter of 2007 on Thursday, October 25. During a conference call on October 25 at 10:30 a.m. (ET), financial information will be reviewed and company executives will address inquiries from investors and analysts.
Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has been ranked first among the top employers in the pharmaceutical and biopharmaceutical industry according to the 2007 Top Employers survey conducted by Science. Science's annual survey polls employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries.
Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
- Details
- Category: Abbott
Abbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine's "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.
Teva Announces Approval of Generic Actonel®
- Details
- Category: Product
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Procter and Gamble Actonel® (Risedronate Sodium) Tablets, 5 mg, 30 mg and 35 mg.
EPO Rules European Nexium® Process Patent Valid
- Details
- Category: AstraZeneca
AstraZeneca announced that the European Patent Office (EPO) Opposition Division has ruled that the European process patent EP 0773940 for Nexium® is valid in amended form, despite an opposition by the German generic manufacturer ratiopharm. The patent has been upheld as granted with regards to claims 1 and 2. Regarding claims 3 and 4, minor amendments have been made.
Aptivus® (tipranavir) capsules granted full approval by the U.S. FDA
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus® (tipranavir) capsules. The FDA granted accelerated approval to Aptivus in June 2005; accelerated approval is a regulatory process that expedites the approval of therapies for serious or life-threatening illnesses.
Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis
- Details
- Category: Novartis
Aclasta® (zoledronic acid 5 mg) has received European Union approval as the first once-yearly treatment for women with postmenopausal osteoporosis. The announcement closely follows the recent approval in the US, where the Food and Drug Administration (FDA) approved Aclasta under the brand name Reclast® in August 2007. The European Commission decision applies to all 27 member states, Norway and Iceland.
More Pharma News ...
- GSK seeks prequalification for Cervarix⢠from the World Health Organization
- Shire's ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome
- Pfizer Launches Independent Biotherapeutics and Bioinnovation Center
- Boehringer Ingelheim comments the nevirapine production for Rwanda by Apotex
- GSK applies for licence to market OTC weight loss product In Europe
- Herceptin eradicates tumours and may reduce the need for mastectomies
- Bionas Signs Service Contract with Solvay Pharmaceuticals